South San Francisco, CA · Founded 2019 · Privately Held (backing)
Developer of a broad-spectrum vaccine designed to treat and eradicate rapidly mutating pathogens. Centivax is based in South San Francisco, CA and was founded in 2019. Its last reported valuation was $95 million in Jul 2025. It has raised $92 million.
Last reported valuation
$95.0M
Oct 2026
Priced at
—
Total raised
$92.0M
Last round
—
Cap table — not yet on record
Centivax's share-class structure hasn't surfaced in our sources yet. Cap tables are assembled from certificates of incorporation, round filings, and disclosures as they land.
Pro members can request priority coverage with a 48-hour turnaround.
Free account
More of Centivax with a free account
·The complete investor list: 14 names
·Watch Centivax: the Monday email on marks, rounds and moves
